Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. (NASDAQ: CERT) is a software‑driven company in the model‑informed drug development and biosimulation space. The CERT news page on Stock Titan aggregates company‑specific headlines so readers can follow how Certara’s biosimulation software, technology, and services are discussed in earnings releases, product announcements, scientific updates, and corporate events.
Recent Certara news highlights several recurring themes. The company issues quarterly financial results that describe revenue from biosimulation software and services, bookings trends, and updates to its full‑year financial outlook. These results are typically accompanied by commentary on demand for model‑informed drug development solutions and the performance of its software and services portfolio.
Certara also regularly announces new software capabilities and platform enhancements. Examples in recent releases include the launch of Certara IQ, an AI‑powered quantitative systems pharmacology solution, and TFL Studio, the first cloud‑native module of its Phoenix Cloud platform for pharmacokinetic and pharmacodynamic workflows. The company has additionally introduced Pinnacle 21 Enterprise Plus for managing CDISC SDTM and ADaM data specifications used in regulatory submissions.
Another category of news involves scientific recognition and research output, such as announcements about Certara scientists being listed among highly cited researchers and the publication of hundreds of scientific papers in a year. Corporate governance and leadership updates, including changes in the chief executive officer role, appear in both press releases and related SEC filings.
Investors, analysts, and industry professionals can use this news feed to monitor Certara’s financial disclosures, product roadmap, scientific contributions, and capital markets activity over time.
Certara (CERT), a leader in model-informed drug development, has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to present on Wednesday, January 15th, 2025, at 5:15 PM Pacific Time.
Investors and interested parties can access a live webcast of the presentation through Certara's investor relations website at https://ir.certara.com. The presentation recording will remain available for replay on the website for a minimum of 30 days following the event.
Certara (Nasdaq: CERT) highlights its 2024 research achievements with over 100 publications and recognition of 12 company scientists in the Stanford/Elsevier top 2% cited researchers list. The publications cover diverse areas including pediatric oncology, first-in-human dose predictions, exposure-response analyses, and the application of PBPK modeling in global health. Notable research trends focused on biosimulation strategies in drug development and extended model-informed drug development, including the implementation of generative AI in regulatory writing and diversity in clinical trial enrollment.
Certara (NASDAQ: CERT) reported Q3 2024 financial results with revenue of $94.8 million, up 11% year-over-year. Software revenue grew 15% to $35.9 million, while services revenue increased 9% to $58.9 million. The company posted a net loss of $1.4 million, significantly improved from a $49.0 million loss in Q3 2023. Adjusted EBITDA rose 15% to $33.1 million. Total bookings grew 13% to $96.1 million. The company updated its full-year 2024 guidance, expecting revenue between $380-385 million and adjusted EBITDA of $120-124 million.
Certara (Nasdaq: CERT), a global leader in model-informed drug development, has announced its participation in the Stephens Annual Investment Conference. The company's management will deliver a presentation on Thursday, November 21st, 2024, at 10:00 AM CT. Investors and interested parties can access a live webcast of the presentation through Certara's investor relations website at https://ir.certara.com. The presentation recording will remain available for replay for a minimum of 90 days following the event.
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed John Reynders, PhD, to its Board of Directors, effective October 15, 2024. Dr. Reynders brings over 25 years of experience in the pharmaceutical and tech industries, with expertise in artificial intelligence, data science, and life science.
Dr. Reynders' career highlights include serving as the founding CIO of Moderna, where he led data-sciences capabilities for mRNA therapy design, and as Chief Data Sciences Officer at Neumora. He has also held executive positions at Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly, and Celera.
Certara's CEO, William F. Feehery, PhD, expressed excitement about the appointment, emphasizing the value Dr. Reynders' expertise will bring to the company's ongoing development of transformational software and services for accelerating new medicines and increasing pharma R&D productivity.
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has announced it will release its financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. The company management will host a conference call to discuss the financial results at 5:00PM ET. Investors interested in participating in the conference call are required to register online, with registration recommended at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of Certara's website at https://ir.certara.com/.
Certara, Inc. (Nasdaq: CERT), a leader in model-informed drug development, has completed the acquisition of Chemaxon, a developer of scientific informatics software for in-silico research in the life sciences industry. The combined organization aims to offer improved predictive biosimulation and scientific informatics capabilities to enhance decision-making from discovery through commercialization.
Key points:
- Integration plans include incorporating Chemaxon's chemistry structures, calculators, and predictors into Certara's D360 applications and Simcyp™ PBPK Simulator.
- Long-term plans involve leveraging Certara.AI's specialized GPT capabilities and expanding pharmacokinetics and pharmacodynamics knowledge in drug discovery processes.
- Chemaxon is expected to generate software revenue exceeding $20 million in 2024.
- Certara will update its 2024 guidance to include Chemaxon's contribution in its third-quarter earnings report in November.
Certara (Nasdaq: CERT) celebrates the 25th anniversary of its Simcyp Consortium, a pre-competitive scientific research group comprising 35 leading biopharmaceutical companies. The consortium has become a global authority on physiologically-based pharmacokinetic (PBPK) modeling and simulation.
The Simcyp Simulator, used by pharmaceutical companies, academia, and regulatory agencies, has informed dosing decisions for over 375 label claims across 115+ drugs. It accurately predicts drug behavior in the human body, aiding various stages of drug development.
The consortium has awarded grants totaling $1.4 million to support 13 PhD and postdoctoral researchers. Simcyp provides academic licenses to more than 110 universities worldwide, and its publications have been cited over 8,000 times in scientific literature.
Certara (Nasdaq: CERT) and Ichnos Glenmark Innovation (IGI) collaborated on optimizing the first-in-human dosing strategy for ISB 2001, a trispecific T-cell engager for cancer treatment. The research, published in Nature Cancer, used virtual trials to select a higher starting dose, increasing it by 50-100 fold over conventional methods. This approach, approved by the FDA and Australian HREC, aims to reduce costs, minimize ineffective dosing, and accelerate drug development.
The collaboration leveraged Certara's expertise in quantitative systems pharmacology and physiologically-based pharmacokinetics to develop a virtual clinical trial platform. This innovative method not only enhances patient safety and efficacy but also aligns with regulatory goals to reduce animal studies. The optimized dosing strategy for ISB 2001 showcases the potential of virtual patient technology in drug development, particularly for complex biologics like T-cell engagers.
Certara (Nasdaq: CERT), a leader in model-informed drug development, has announced its participation in two upcoming investor conferences. The company will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 4:05 p.m. ET and the Baird Global Healthcare Conference on September 11 at 10:15 a.m. ET.
Both conference presentations will be available via live webcasts on Certara's investor relations website at https://ir.certara.com. These webcasts will remain accessible for replay for at least 90 days after the events. This participation provides investors with opportunities to gain insights into Certara's operations and future prospects directly from the company's management.